(PharmaNewsWire.Com, June 22, 2017 ) Rapid increase in the geriatric population across the world, coupled with the rising prevalence of various disorders such as obesity and hypertension, as a result, is pushing the global atrial fibrillation market significantly. In recent years, the favorable results of clinical trials of drugs and therapies intended for the treatment of atrial fibrillation have supported the growth of this market. A fresh review analysis on the ongoing clinical trials has been presented in a study titled as “ Atrial Fibrillation Global Clinical Trials Review, H1, 2017 ”, which has been added to the mega-repository of Market Research Hub (MRH).
The report identifies that there are numerous ongoing clinical trials on atrial fibrillation (AF) currently taking place, which are aiming to improve the treatment of the disease condition. This 150-pages research study provides a snapshot of the global clinical trials landscape and offers top-level data related to the clinical trials by covering some major regions, country (G7 & E7), trial phase, trial status, sponsor type and end point status. Moreover, enrollment trends for the past five years and latest news & press releases regarding these clinical trials for the past three months are outlined.
Atrial fibrillation (also called AFib or AF) is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications. Atrial fibrillation (AF) is the most common cardiac arrhythmia in the United States. Each year millions of Americans are diagnosed and treated for this condition. Although up to 90% of AF episodes may not cause symptoms, many patients experience a wide variety of symptoms, including palpitations, dyspnea, fatigue, dizziness, angina, and decompensated heart failure. It has been estimated that atrial rhythm changes occur in about 4% of the population and it affects approximately 2.2 million people, in the U.S.
The study further includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The precise analysis of clinical trials is collated from 80+ different clinical trial registries, conferences, journals, news etc. The treatment goals of atrial fibrillation (AF or AFib) start with a proper diagnosis through an in-depth examination from a physician. Currently, one of the most widely used treatments is catheter ablation that involves radiofrequency energy or freezing directed through a catheter to specific heart cells.
Moving further, the report reviews top companies involved and enlists all their active and ongoing trials (Trial title, Phase, and Status) pertaining to the company. Atrial fibrillation therapeutics clinical trials, in the global market, together with ongoing clinical trials by prominent drugs are also highlighted. By the above information, the report enhances the decision-making capabilities and helps market players to create some effective counter-strategies to gain competitive advantage.
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of Pharmaceutical Market Research Reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps..
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
